Stem Cells in Drug Discovery

Date: Monday, 6 March 2017 - Tuesday, 7 March 2017
Location: Wellcome Genome Campus Conference Centre, Cambridge, UK

Keynote Speakers

Christine Mummery
Professor and Chair of Developmental Biology, Leiden University Medical Centre

Ludovic Vallier
Professor, University Of Cambridge

Overview

SELECTBIO is thrilled to announce the continuation of Stem Cells in Drug Discovery for 2017.

Owing to the success of the meeting in 2015 and 2016, this will be a larger, multi-track event being held alongside Antibodies in Drug Discovery, Epigenetics in Drug Discovery and Academic Drug Discovery. Taking place at the Wellcome Genome Campus Conference Centre in Cambridge, UK on 6 - 7 March 2017, attendees will benefit from unrestricted access to all four tracks.

Progress in developmental and stem cell biology is revolutionising drug discovery research; the ability to grow and differentiate stem cell lines is providing a far more relevant model for pre-clinical testing. So much so that the FDA is looking into replacing previous models as a matter of urgency. However, challenges in assay development, scale up and quality control still persist and need to be addressed in order for success in this field to continue.

Stem Cells in Drug Discovery 2017 will see an even larger event with more talks, attendees and discussions than ever before. Hear from and network with researchers who are currently screening for efficacy and toxicity using iPS cell lines, and those responsible for developing the techniques and technologies enabling them to do so. There will also be discussions on industry and regulatory developments that are shaping the future of drug discovery.

Registration includes unrestricted access to all conference tracks and a reception dinner at the end of the first day.

SELECTBIO is offering a limited number of student bursaries at this event. Find out more

Agenda Topics

3D Cell Based Models
Cellular Reproducibility and Robustness
Disease Modelling
Scale Up and Quality Control
Screening and Drug Discovery Assays

Sponsorship and Exhibition Opportunities

Exhibition Team,
exhibitors@selectbio.com
+44 (0) 1206 501654

Confirmed Speakers to date

Amanda Cobos-Correa, Lab Head Screening Sciences, Novartis Institutes for Biomedical Research
Davide Danovi, Director, Cell Phenotyping Platform, Kings College London
Daniel Gaffney, Group Leader, Wellcome Trust Sanger Institute
Mina Gouti, Group Leader, Max-Delbrück Center for Molecular Medicine
Stephen Hague, Droplet Digital PCR Specialist Europe, Bio-Rad Laboratories Inc
Mark Hewitson, Account Manager, Cellular Dynamics Intl
Ryan Hicks, Associate Director, AstraZeneca
Jey Jeyakumar, Principal Scientist & Group Leader, Plasticell & Progenitor Therapeutics
Ivan Kopljar, Post Doctorial Research Scientist, The Janssen Pharmaceutical Companies of Johnson & Johnson
Chulan Kwon, Associate Professor, Johns Hopkins University
Annamaria Lilienkampf, Research and Teaching Fellow, Edinburgh University
Cathy Merry, Associate Professor of Stem Cell Glycobiology, University of Nottingham
Stephen Minger, Director, SLM Blue Skies Innovations, Ltd
Keiko Muguruma, Research Specialist, RIKEN Center for Developmental Biology (CDB)
Jens Vinge Nygaard, Head of Section & Associate Professor, Aarhus University
Roger Pedersen, Professor, University of Cambridge
Tamir Rashid, MRC Clinician Scientist Fellow, King's College London
Angela Russell, Professor, University of Oxford
Devyn Smith, Chief Operating Officer, Sigilon
Glyn Stacey, Principal Scientist and Head of Cell Biology, National Institute for Biological Standards and Control (NIBSC)
Yang Teng, Associate Professor, Harvard Medical School
Emily Titus, Director, Technology Development, Centre for Commercialization of Regenerative Medicine (CCRM)